JACC: Cardiovascular Interventions · 2020 · 78 citations · 29 references
MedicineCardiologySurgeryInterventional CardiologyPulmonologyUltrasonographyPulmonary HypertensionPulmonary Vascular DiseaseVascular UltrasonographyVasodilator TherapyClinical Trial Efficacy EndpointsMedication-related Adverse EventsMulticenter TrialsOpen-label TrialsPulmonary Vascular Resistance AssessmentSecondary Efficacy EndpointsSerious Adverse EventsVascular Resistance
OBJECTIVES: The aim of this study was to investigate whether therapeutic intravascular ultrasound pulmonary artery denervation (PDN) is safe and reduces pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension (PAH) on a minimum of dual oral therapy. BACKGROUND: Early studies have suggested that PDN can reduce PVR in patients with PAH. METHODS: TROPHY1 (Treatment of Pulmonary Hypertension 1) was a multicenter, international, open-label trial undertaken at 8 specialist centers. Patients 18 to 75 years of age with PAH were eligible if taking dual oral or triple nonparenteral therapy and not responsive to acute vasodilator testing. Eligible patients underwent PDN (TIVUS System). The primary safety endpoint was procedure-related adverse events at 30 days. Secondary endpoints included procedure-related adverse events, disease worsening and death to 12 months, and efficacy endpoints that included change in pulmonary hemodynamic status, 6-min walk distance, and quality of life from baseline to 4 or 6 months. Patients were to remain on disease-specific medication for the duration of the study. RESULTS: (p = 0.001) or 17.8%, which was associated with a 42 ± 63 m (p = 0.02) increase in 6-min walk distance and a 671 ± 1,555 step (p = 0.04) increase in daily activity. CONCLUSIONS: In this multicenter early feasibility study, PDN with an intravascular ultrasound catheter was performed without procedure-related adverse events and was associated with a reduction in PVR and increases in 6-min walk distance and daily activity in patients with PAH on background dual or triple therapy.
29
Nazzareno Galiè, Marius M. Hoeper, Marc Humbert et al. · European Heart Journal · 2009 · 3.9K citations · Full text
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Tomás Pulido, Igor Adzerikho, Richard N. Channick et al. · New England Journal of Medicine · 2013 · 1.4K citations · Full text
David E. Kandzari, Michael Böhm, Felix Mahfoud et al. · The Lancet · 2018 · 776 citations
Medicine, Cardiology, Pharmacology +11
Raymond R. Townsend, Felix Mahfoud, David E. Kandzari et al. · The Lancet · 2017 · 734 citations
Medicine, Cardiology, Nephrology +10